Atopic Dermatitis

Peter Lio, MD, offers perspectives on topical steroid withdrawal, also known as red skin syndrome or topical steroid addiction.

Audrey Dean discusses her experience of atopic dermatitis therapeutic side effects with her dermatologist, Jennifer Holman, MD, FAAD. Jennifer Holman goes on to highlight key pearls on managing patients with atopic dermatitis.

Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.

Natural and synthetic antimicrobial peptides can penetrate deeper skin layers.

Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

Investigators found a steady reduction of IgE levels in patients regardless of dupilumab dosing interval.

Roflumilast cream .05% for mild to moderate atopic dermatitis in children also met secondary endpoints.

The Small Business Innovation Research grant enables ResVita Bio to develop RVB-101 for treatment of severe atopic dermatitis.

Skin clearance and itch relief were maintained through 1 year of treatment with monthly maintenance.

According to researchers, only 3 studies have previously explored a potential link between AD and dementia with inconsistent findings.

World Atopic Eczema Day initiative from Almirall highlights experiences and facts about atopic dermatitis.

Nektar Therapeutics announced the promising and statistically significant results, which included meeting endpoints of BSA, DLQI and POEM in patients with atopic dermatitis.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial diagnosis experience. Jennifer Holman goes on to describe how different patient populations struggle to access quality care.

Audrey Dean and her dermatologist, Jennifer Holman, MD, FAAD, discuss the importance of having a network of support when diagnosed with atopic dermatitis.

The submission follows the announcement of recent long-term data of the drug in patients ages 6 years and older.

Roflumilast maintained disease control when patients switched to twice-weekly dosing.

The review found that utilizing dupilumab to treat these patients with AD cost more than using baricitinib, although dupilumab was more effective.

As we approach National Eczema Week and National Eczema Month, take a look at the most influential atopic dermatitis research from the last decade.

Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial symptoms and how the disease impacted her quality of life (QoL). Jennifer Holman reflects on how her practice and approaches have changed as she learned more about the daily impact of atopic dermatitis.

A dermatologist and her patient discuss the pathophysiology and major comorbidities of atopic dermatitis (AD), highlighting the main differences between adult and adolescent AD.

Two poster presentations at this year’s Society for Pediatric Dermatology Meeting delve into the psychological impact of the condition and a new option for management.